The ASX is so painful to watch sometimes.
Bugger all volume on most stocks and people just consumed by lithium play and the odd random energy stocks evidenced every day by the most active and advancers.
Best bet here would be a slow growth followed by a takeover by a bigger fish.
If sound product sales aren't going to flick the switch here, then we are reliant on:
- CLIA waiver for Febridx
- Full FDA approval for Viradx (not EUA)
- Other partnership deals coming to fruition ( Food in Depth, Aptatek, Micropak etc)
- Random new partnership
Hopefully the company provides some clarity next week with the annual report on exactly what the status is with some of these clients and we see some positive uptake.
Add to My Watchlist
What is My Watchlist?
